CAJ | 학술논문

目的：探讨匹多莫德对呼吸道感染患者临床疗效及免疫功能影响。方法选取秦皇岛市第三医院、包钢集团第三职工医院、乌兰察布市第三医院收治的反复呼吸道感染患者120例，按照随机数字表达法分为2组，其中对照组60例，予抗感染、止咳、化痰、退热常规治疗；实验组60例，在常规治疗的基础上加用匹多莫德颗粒，0.4 g开水冲服，每日2次，60 d为1个疗程，治疗1个疗程。治疗后，对比2组临床疗效及治疗前后患者血清免疫球蛋白水平（IgG、IgA、IgM），T淋巴细胞亚群（CD3＋、CD4＋、CD8＋）和NK细胞相对活性。结果治疗后实验组总有效率（95.00％）明显高于对照组（81.67％），差异有统计学意义（P＜0.05）；2组患者治疗前各免疫指标水平无显著性差异，治疗后实验组血清免疫球蛋白IgG、IgA、IgM及T淋巴细胞亚群CD3＋、CD4＋、CD8＋水平较对照组明显上升，差异有统计学意义（P＜0.05）；治疗后实验组NK细胞相对活性明显比对照组升高，差异有统计学意义（P＜0.05）；2组患者在治疗期间均出现较轻微皮疹、贫血等不良反应，且不良反应发生率无显著性差异，经对症处理后，不良反应可耐受。结论匹多莫德能够明显提高呼吸道感染患者临床疗效，有效改善反复呼吸道感染患者免疫功能，安全性较高，对临床具有指导意义。
목적：탐토필다막덕대호흡도감염환자림상료효급면역공능영향。방법선취진황도시제삼의원、포강집단제삼직공의원、오란찰포시제삼의원수치적반복호흡도감염환자120례，안조수궤수자표체법분위2조，기중대조조60례，여항감염、지해、화담、퇴열상규치료；실험조60례，재상규치료적기출상가용필다막덕과립，0.4 g개수충복，매일2차，60 d위1개료정，치료1개료정。치료후，대비2조림상료효급치료전후환자혈청면역구단백수평（IgG、IgA、IgM），T림파세포아군（CD3＋、CD4＋、CD8＋）화NK세포상대활성。결과치료후실험조총유효솔（95.00％）명현고우대조조（81.67％），차이유통계학의의（P＜0.05）；2조환자치료전각면역지표수평무현저성차이，치료후실험조혈청면역구단백IgG、IgA、IgM급T림파세포아군CD3＋、CD4＋、CD8＋수평교대조조명현상승，차이유통계학의의（P＜0.05）；치료후실험조NK세포상대활성명현비대조조승고，차이유통계학의의（P＜0.05）；2조환자재치료기간균출현교경미피진、빈혈등불량반응，차불량반응발생솔무현저성차이，경대증처리후，불량반응가내수。결론필다막덕능구명현제고호흡도감염환자림상료효，유효개선반복호흡도감염환자면역공능，안전성교고，대림상구유지도의의。
Objective To explore the clinical curative effect of pidotimod on patients with respiratory tract infection and effect on immune function. Methods 120 children with recurrent respiratory tract infection in the Third Hospital of Qinhuangdao,the Third Staff Hospital of Baogang Group,the Third Hospital of Wulanchabu were selected,and were divided into two groups according to random number table.60 cases in control group were treated with routine treatment of anti-infection,relieving cough,eliminating phlegm,antipyretic;60 cases in experimental group were treated with pidotimod on the basis of routine treatment,oral with boiled water,0.4g per times,2 times a day,with a course of 60 days.Clinical curative effect after treatment and serum immunoglobulin (IgG,IgA,IgM)levels,T lymphocyte subsets (CD3+,CD4+,CD8+)levels and NK cells relative activities before and after treatment were compared between two groups.Results After treatment,the total effective rate of experimental group (95.00%)was significantly higher than that of control group (81.67%),and the difference was statistically significant (P<0.05);the immune indexes before treatment had no significant difference,and levels of serum immunoglobulin and T lymphocyte subsets were improved,and levels of serum immunoglobulin (IgG,IgA,IgM)and T lymphocyte subsets (CD3+,CD4+,CD8+)of experimental group were more higher than those of control group,and the difference was statistically significant (P<0.05 );relative activity of NK cells in both groups improved after treatment,but relative activity of NK cells in experimental group was significantly higher than that in control group,and the difference was statistically significant (P<0.05 );adverse reactions according minor rashes and anemia were observed in two groups,and there was no significant differece in the incidence of adverse reactions,and ADR was tolerable after symptomatic treatment.Conclusion Pidotimod could significantly improve the clinical curative effect of patients with respiratory tract infections and effectively improve the immune function of patients with recurrent respiratory tract infections with high security,which has a clinical significance.